General Information of Drug Off-Target (DOT) (ID: OTW9L6S4)

DOT Name RNA polymerase II subunit A C-terminal domain phosphatase SSU72 (SSU72)
Synonyms CTD phosphatase SSU72; EC 3.1.3.16
Gene Name SSU72
UniProt ID
SSU72_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
PDB ID
3O2Q; 3O2S; 4H3H; 4H3K
EC Number
3.1.3.16
Pfam ID
PF04722
Sequence
MPSSPLRVAVVCSSNQNRSMEAHNILSKRGFSVRSFGTGTHVKLPGPAPDKPNVYDFKTT
YDQMYNDLLRKDKELYTQNGILHMLDRNKRIKPRPERFQNCKDLFDLILTCEERVYDQVV
EDLNSREQETCQPVHVVNVDIQDNHEEATLGAFLICELCQCIQHTEDMENEIDELLQEFE
EKSGRTFLHTVCFY
Function
Protein phosphatase that catalyzes the dephosphorylation of the C-terminal domain of RNA polymerase II. Plays a role in RNA processing and termination. Plays a role in pre-mRNA polyadenylation via its interaction with SYMPK.
KEGG Pathway
mR. surveillance pathway (hsa03015 )
Reactome Pathway
RNA polymerase II transcribes snRNA genes (R-HSA-6807505 )

Molecular Interaction Atlas (MIA) of This DOT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
3 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate increases the methylation of RNA polymerase II subunit A C-terminal domain phosphatase SSU72 (SSU72). [1]
Arsenic DMTL2Y1 Approved Arsenic affects the methylation of RNA polymerase II subunit A C-terminal domain phosphatase SSU72 (SSU72). [7]
Bisphenol A DM2ZLD7 Investigative Bisphenol A increases the methylation of RNA polymerase II subunit A C-terminal domain phosphatase SSU72 (SSU72). [10]
------------------------------------------------------------------------------------
7 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Ciclosporin DMAZJFX Approved Ciclosporin decreases the expression of RNA polymerase II subunit A C-terminal domain phosphatase SSU72 (SSU72). [2]
Acetaminophen DMUIE76 Approved Acetaminophen increases the expression of RNA polymerase II subunit A C-terminal domain phosphatase SSU72 (SSU72). [3]
Doxorubicin DMVP5YE Approved Doxorubicin increases the expression of RNA polymerase II subunit A C-terminal domain phosphatase SSU72 (SSU72). [4]
Cupric Sulfate DMP0NFQ Approved Cupric Sulfate decreases the expression of RNA polymerase II subunit A C-terminal domain phosphatase SSU72 (SSU72). [5]
Ivermectin DMDBX5F Approved Ivermectin decreases the expression of RNA polymerase II subunit A C-terminal domain phosphatase SSU72 (SSU72). [6]
APR-246 DMNFADH Phase 2 APR-246 affects the expression of RNA polymerase II subunit A C-terminal domain phosphatase SSU72 (SSU72). [8]
PMID28460551-Compound-2 DM4DOUB Patented PMID28460551-Compound-2 increases the expression of RNA polymerase II subunit A C-terminal domain phosphatase SSU72 (SSU72). [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Drug(s)

References

1 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
2 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
3 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
4 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
5 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
6 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
7 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
8 Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene. 2010 Mar 4;29(9):1329-38. doi: 10.1038/onc.2009.425. Epub 2009 Nov 30.
9 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
10 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.